NextPoint Therapeutics announces $80 million Series B financing co-led by Leaps by Bayer and Sanofi Ventures to advance novel immuno-oncology programs
- Details
- Category: Bayer
![Bayer Bayer](/images/logo/bayer.png)
AstraZeneca to acquire CinCor Pharma to strengthen cardiorenal pipeline
- Details
- Category: AstraZeneca
![AstraZeneca AstraZeneca](/images/logo/astrazeneca.png)
Pfizer announces positive top-line results from Phase 3 study of hemophilia B gene therapy candidate
- Details
- Category: Pfizer
![Pfizer Pfizer](/images/logo/pfizer.png)
VidPrevtyn Beta COVID-19 booster vaccine, developed by Sanofi and GSK, approved for use in Great Britain
- Details
- Category: GlaxoSmithKline
![GlaxoSmithKline GlaxoSmithKline](/images/logo/gsk.png)
Pfizer announces FDA and EMA acceptance of etrasimod regulatory submissions for ulcerative colitis
- Details
- Category: Pfizer
![Pfizer Pfizer](/images/logo/pfizer.png)
Recombinant adeno-associated virus (rAAV) technology pioneered by AskBio's Dr. Jude Samulski is key component of all FDA approved AAV gene therapeutics
- Details
- Category: Bayer
![Bayer Bayer](/images/logo/bayer.png)
Roche announces U.S. collaboration with Pfizer to help patients who test positive for COVID-19 navigate risks, symptoms, testing and treatment options
- Details
- Category: Roche
![Roche Roche](/images/logo/roche.png)
More Pharma News ...
- GSK and Wave Life Sciences announce collaboration to drive discovery and development of oligonucleotide therapeutics focusing on novel genetic targets
- Bayer launches industry-first public database listing company's science collaborations and partnerships in the U.S.
- Pfizer and Clear Creek Bio to collaborate on a research program targeting SARS-CoV-2 papain-like protease
- Bayer supports rebuilding of Ukrainian healthcare system by donating 1.3 million euros
- Eisai and Biogen announced the results from large global Phase 3 confirmatory Clarity AD clinical study of lecanemab
- AstraZeneca to acquire Neogene Therapeutics, accelerating ambition in Oncology cell therapy
- Pfizer and BioNTech report new data on Omicron BA.4/BA.5-adapted bivalent booster